| Status | Study |
| Not yet recruiting |
Study Name: Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease Condition: Acute Graft Versus Host Disease Date: 2017-05-16 Interventions: Biological: MSCTC-0010 Dose Escalation Cohort 1: 2.0 × |
| Recruiting |
Study Name: Fecal Microbiota Transplantation in Gut aGVHD Treated Condition: Acute-graft-versus-host Disease Date: 2017-05-05 Interventions: Biological: Fecal microbiota fecal microbiota transplantation |
| Not yet recruiting |
Study Name: GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease Condition: Acute Graft-versus-host Disease Date: 2017-05-02 Interventions: Drug: Itacitinib Itacitinib at |
| Recruiting |
Study Name: Topical Vitamin D in Acute Graft Versus Host Disease of the Skin Condition: Graft Vs Host Disease Date: 2017-03-23 Interventions: Dietary Supplement: Calcipotriene Topical vitamin D cream will be applied to affected areas of the skin. |
| Not yet recruiting |
Study Name: Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant Condition: Childhood Malignant Neoplasm Hematopoietic Cell Transplantation Recipient Date: 2017-02-15 Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation |
| Recruiting |
Study Name: Ruxolitinib for Steroid-refractory GVHD Condition: Graft Vs Host Disease Date: 2016-12-14 Interventions: Drug: Ruxolitinib Oral Tablet Dose reduction criteria for |
| Recruiting |
Study Name: Preemptive Adoptive CMV-CTL Infusion to Prevent Refractory CMV Infection Post Haplo-HSCT Condition: CMV Infection Date: 2016-11-28 Interventions: Biological: Donor-derived CMVpp65-specific T cells About 1 million per kg CMVpp65-specific T cells will |
| Recruiting |
Study Name: A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1) Condition: Graft-versus-host Disease Date: 2016-11-01 Interventions: Drug: Ruxolitinib Other Names: |
| Recruiting |
Study Name: A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD Condition: Graft Versus Host Disease Date: 2016-10-24 Interventions: Biological: GLASSIA Other Name |
| Recruiting |
Study Name: A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease Condition: Graft vs Host Disease Date: 2016-10-03 Interventions: Biological: Mesenchymoangioblast-derived mesenchymal stem cells The active agent in CYP-001 is allogenei |